BE446238A - - Google Patents
Info
- Publication number
- BE446238A BE446238A BE446238DA BE446238A BE 446238 A BE446238 A BE 446238A BE 446238D A BE446238D A BE 446238DA BE 446238 A BE446238 A BE 446238A
- Authority
- BE
- Belgium
- Prior art keywords
- solution
- hemin
- blood
- gelatin
- hemoglobin
- Prior art date
Links
- BTIJJDXEELBZFS-QDUVMHSLSA-K Hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 claims description 8
- 229940025294 Hemin Drugs 0.000 claims description 7
- 210000004369 Blood Anatomy 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 239000000084 colloidal system Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000001681 protective Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 150000002506 iron compounds Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000018146 globin family Human genes 0.000 description 3
- 108060003196 globin family Proteins 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N Carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- BTIJJDXEELBZFS-UHFFFAOYSA-K Hemin Chemical compound [Cl-].[Fe+3].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 BTIJJDXEELBZFS-UHFFFAOYSA-K 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 230000037227 Blood Loss Effects 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HLUCICHZHWJHLL-UHFFFAOYSA-N Hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 210000003324 RBC Anatomy 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
<Desc/Clms Page number 1>
Procedé pour la préparation d'un liquide de remplace-
EMI1.1
w..e....-..,...-......-....-.-..-a.-..--.-...----.--- ..-.----.. ment du sang. our empêcher une disparition rapide d'une solution physiologique de sel de cuisine ou d'une solution de Ringer introduite après des pertes de sang, hors du système circu- latoire, on y a ajouté des colloïdes proteoteurs, par exemple de la gomme arabique, de la gélatine, etc.. (voir R.E. Lie- segang, Kollold tsohr. Fascicule 10, page 224, 1912).
Outre la combinaison avec l'eau, on obtient ainsi également une meilleure adaptation à la viscosité du sang.
Il manque encore dans les préparations de ce genre un constituant essentiel si on les oompare aux constituants ohi- @ miques du sang, savoir les composés de fer. Ils existent dans le sang comme on le sait principalement à l'état d'hé- moglobine qui sert au transport de l'oxygène des poumons vers l'intérieur (et de J'acide carbonique suivant le trajet inverse). Le plasma contient en quantité plus minime d'au- tres composés de fer combinés organiquement, par exemple le fer facilement dissociable suivant Barkan qui excite la formation à nouveau de globules rouges oontenant l'hémo-
<Desc/Clms Page number 2>
globine dans la moëlle rouge des os.
Lorsqu'on veut ajouter des composés de fer à la solution de Hinger pour qu'ils rem- plissent la fonction mentionnée en dernier lieu et également celle de l'hémoglobine, il est nécessaire qu'ils soient pré- sents par combinaison à une matière organique en un complexe colloïdal pour qu'une diffusion soit empêchée autant que pos- sible. Dans l'hémoglobine, ceci est assuré par la combinai- son de la petite partie d'hémine contenant le fer à la grande globine exempte de fer.
Une hémoglobine quelconque ne peut pas être ajoutée au liquide de remplacement car le constituant globine est une albumine de nature spéciale. L'addition d'hémine ou d'héma- tine seule ne réussit pas directement, car sa solubilité dans le liquide pratiquement neutre est trop minime.
Moyennant l'utilisation des colloïdes protecteurs connus pour des solutions d'injection, on parvient toutefois à faire passer l'hémine ou les autres composés de fer exempts d'albu- mine contenus dans l'hémoglobine, dansle cas d'une concentra- tion satisfaisante, dans une solution colloïdale et par consé- quent non susceptible de diffusion.
Il a été découvert que l'on obtient une solution d'hémi- ne convenant comme liquide de remplacement du sang lorsqu'on met l'hémine en solution d'abord à l'aide d'alcalis, comme l'hydroxyde de sodium. La solution alcaline de l'hémine est alors mélangée à la solution du colloïde protecteur, par exem- ple la gélatine et est neutralisée au moyen de la quantité équivalente d'acide chlorhydrique. Il ne se produit pas alors de précipitation de l'hémine comme ce serait le cas en l'absence du colloïde protecteur mais l'hémine reste sous la forme de solution colloïdale. L'absence du pouvoir de diffu- sion peut se démontrer lorsqu'on met en bouche une semblable solution dans un tube à réaction au-dessus d'une gelée de gé-
<Desc/Clms Page number 3>
latine à 10%.
La couche de séparation ne se déplace pas, mê- me après plusieurs jours.
La teneur en hydroxyde de sodium eten acide chlorhydri- que peut facilement être réglée de telle manière que le liqui- de contient ultérieurement 0,9% NaCl.
Exemple :.
Hémine 0,25 gr. dissous dans 15 cc de solution de soude normale et 20 oc d'eau. Addition à 25 co d'une solution de gélatine 10%.
On ajoute alors avec agitation un mélange de 25 cc d'une solution de gélatine à 10% et de 15 cc diacide chlorhydrique normale.
<Desc / Clms Page number 1>
Procedure for the preparation of a replacement liquid
EMI1.1
w..e ....- .., ...-......-....-.-..- a.-.. -.-...----. --- ..-.---- .. ing blood. In order to prevent a rapid disappearance of a physiological solution of kitchen salt or of a Ringer's solution introduced after blood loss, outside the circulatory system, proteotor colloids, for example gum arabic, have been added to it, gelatin, etc. (see RE Lie- segang, Kollold tsohr. Paper 10, page 224, 1912).
In addition to the combination with water, this also results in a better adaptation to the viscosity of the blood.
Preparations of this kind still lack an essential constituent when compared to the ohemic constituents of blood, namely iron compounds. They exist in the blood, as we know, mainly in the state of hemoglobin, which is used to transport oxygen from the lungs to the interior (and carbonic acid following the reverse route). The plasma contains in smaller quantities other organically combined iron compounds, for example the easily dissociable iron according to Barkan which stimulates the re-formation of red blood cells containing the hemo-.
<Desc / Clms Page number 2>
globin in the red marrow of the bones.
When it is desired to add iron compounds to Hinger's solution so that they fulfill the last mentioned function and also that of hemoglobin, it is necessary that they be present by combination with a material. organic to a colloidal complex so that diffusion is prevented as much as possible. In hemoglobin, this is provided by the combination of the small iron-containing hemin part with the large iron-free globin.
Any hemoglobin cannot be added to the replacement fluid because the globin component is an albumin of a special nature. The addition of hemin or hematine alone is not directly successful because its solubility in the substantially neutral liquid is too low.
By using the known protective colloids for injection solutions, however, it is possible to pass the hemin or the other albumin-free iron compounds contained in the hemoglobin, in the case of a concentration. satisfactory, in a colloidal solution and therefore not susceptible to diffusion.
It has been found that a suitable hemine solution as a blood replacement fluid is obtained when hemine is first dissolved with alkalis, such as sodium hydroxide. The alkaline solution of hemin is then mixed with the solution of the protective colloid, for example gelatin, and is neutralized with the equivalent amount of hydrochloric acid. Hemin does not then precipitate, as would be the case in the absence of the protective colloid, but the hemin remains in the form of a colloidal solution. The absence of diffusing power can be demonstrated when a similar solution is placed in the mouth in a reaction tube above a gelatin of gel.
<Desc / Clms Page number 3>
Latin at 10%.
The separating layer does not shift even after several days.
The content of sodium hydroxide and hydrochloric acid can easily be adjusted so that the liquid subsequently contains 0.9% NaCl.
Example:.
Hemin 0.25 gr. dissolved in 15 cc of normal soda solution and 20 oc of water. Addition to 25 co of a 10% gelatin solution.
A mixture of 25 cc of a 10% gelatin solution and 15 cc of normal hydrochloric acid is then added with stirring.
Claims (1)
Publications (1)
Publication Number | Publication Date |
---|---|
BE446238A true BE446238A (en) |
Family
ID=102415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE446238D BE446238A (en) |
Country Status (1)
Country | Link |
---|---|
BE (1) | BE446238A (en) |
-
0
- BE BE446238D patent/BE446238A/fr unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Keshavjee et al. | The role of dextran 40 and potassium in extended hypothermic lung preservation for transplantation | |
Hamazaki et al. | Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients | |
CA1330307C (en) | Pharmaceutical compositions containing a 3-hydroxybutanoic acid derivative chosen from oligomers of that acid and esters of that acid or of these oligomers with 1,3-butanediol | |
FR2547727A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
BE446238A (en) | ||
Nitter‐Hauge | Poisoning with ethylene glycol monomethyl ether: report of two cases | |
Kippen et al. | Effects of renal fuels on uptake of PAH and uric acid by separated renal tubules of the rabbit | |
Gøtzsche et al. | Changes in plasma free thyroid hormones during cardiopulmonary bypass do not indicate triiodothyronine substitution | |
LU85812A1 (en) | DOSED FORM OF ETOPOSIDE FOR ORAL USE | |
CA1275247C (en) | Process for the solubilization, at the time of use, of a lipophilic active principle in an aqueous solution for intravenous administration | |
EP0746325B1 (en) | Liquid paraffin oil and lactulose-based hypocaloric laxative jelly and method for its preparation | |
Britton et al. | The effects of acute hypoxia on the sheep foetus and some observations on recovery from hypoxia | |
EP0810821A1 (en) | Method for diluting and preserving rabbit semen | |
BE1007926A3 (en) | Pharmaceutical composition containing n-acetyl-cysteine. | |
de Chastonay | De la capacité en oxygène du sang et de sa mesure | |
Baader et al. | Enzymatic generation of triplet acetone: A window to photobiochemistry without light | |
Kittikowit et al. | Lipid peroxidation and renal injury in renal ischemic reperfusion: effect of angiotensin inhibition | |
World Health Organization | Fiches modèles OMS d'information à l'usage des prescripteurs: médicaments utilisés en anesthésie | |
EP0230199B1 (en) | New complex ferric salts of alpha, alpha'-(1,2-ethanediyl diimino)-bis[5-carboxy-2-hydroxybenzeneacetic acid] and the process for their preparation | |
LU85411A1 (en) | COMPOSITIONS AND METHOD FOR STABILIZING ANTHRALIN | |
FR2660552A1 (en) | Novel antiseptic medicinal gels | |
US2110826A (en) | Anesthetic solutions and mixtures for preparing same | |
FR2619715A1 (en) | Isosmotic polyionic glucose solution | |
Brachet et al. | Proanthocyanes de Calluna vulgaris L. séparation et caractérisation de ces substances dans les rameaux verts | |
FR2595373A1 (en) | Wine-based alcoholic drink |